1 / 112

Vector-Borne Infections

Vector-Borne Infections. Neelay Kothari IHA Infectious Diseases August 30 th , 2017. Disclosures. I have no financial or other conflicts of interest to disclose. Objectives. Definitions Clinical Approach Epidemiology Diagnosis Treatment Prevention. Zoonoses - Definition.

horgan
Download Presentation

Vector-Borne Infections

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Vector-Borne Infections Neelay Kothari IHA Infectious Diseases August 30th, 2017

  2. Disclosures I have no financial or other conflicts of interest to disclose.

  3. Objectives • Definitions • Clinical Approach • Epidemiology • Diagnosis • Treatment • Prevention

  4. Zoonoses - Definition • Nonhuman vertebrate reservoir • Transmission directly to humans • From animal • From products derived from the host • Via arthropod intermediate • Recognized infectious syndrome in susceptible hosts

  5. Zoonoses - Definition • Nonhuman vertebrate reservoir • Transmission directly to humans • From animal • From products derived from the host • Via arthropod intermediate (VECTOR-BORNE) • Recognized infectious syndrome in susceptible hosts

  6. Vectors • Living organism that can transmit infectious diseases between humans or from animals to humans • Examples • Mosquitos • Ticks • Sandflies • Triatome bugs • Tsetse flies • Fleas • Black flies • Aquatic snails

  7. Clinical importance • Account for 17% of all infectious diseases • 1 billion annual cases globally • 1 million deaths annually globally

  8. Ever-changing spectrum • Global travel and trade • Urbanization • Agricultural practices • Climate change • Water and sanitation access

  9. Clinical approach: history • Geography • Season of year • Activities • Potential vector exposures • Clinical syndromes • Incubation period

  10. Clinical approach: classification • By vector • By organism • By clinical syndrome • By geographical distribution

  11. Case 1 60 year old cattle farmer from Tennessee Presents in June with Fever, abdominal pain, nausea, SEVERE frontal headache for 3.7 hours T 39.4, HR 104 WBC 10.3K, creatinine 1.4, sodium 128 Recent ticks on his pet dogs

  12. Case 1 • Which of the following is most likely? • Influenza A • Lyme disease • Rocky mountain spotted fever • Babesiosis

  13. Case 1 • Which of the following is most likely? • Influenza A • Lyme disease • Rocky mountain spotted fever • Babesiosis

  14. Tick-borne infections (United States) • Uncommon Infections • STARI (Southern tick-associated rash illness) • Tickbornerelapsing fever • Tularemia • Powassan disease • Heartland virus • Bourbon virus • Borreliamayonii • Borreliamiyamotoi • Colorado tick fever • Rickettsia parkeri rickettsiosis • 364D rickettsiosis • Common Infections • Lyme disease • Spotted Fever Rickettsiosis • Anaplasmosis • Ehrlichiosis • Babesiosis

  15. Tick appearance

  16. Rocky Mountain Spotted Fever • Etiology: Rickettsia rickettsii (gram-negative obligate intracellular organism) • Ticks: • American dog tick (Dermacentorvariabilis) • Rocky mountain wood tick (Dermacentorandersoni) • Brown dog tick (Rhipicephalussanguineus)

  17. Rocky Mountain Spotted Fever: Epidemiology

  18. Rocky Mountain Spotted Fever: Clinical presentation • Incubation 2-14 days (most commonly 5-7 days) • Early – nonspecific (fever, headache, myalgias, arthralgias, nausea, abdominal pain) • Rash • Initially uncommon (14% at day 1 of symptoms) • 88-90% will develop, usually between days 3-5 • Blanching erythematous rash with macules, becomes petechial • Usually starts on ankles and wrists, and spreads proximally

  19. Rocky mountain spotted fever • Diagnosis • Characteristic signs and symptoms with epidemiologic history • Serology • Antibodies appear 7-10 days after onset of symptoms • Acute and convalescent serologies • Skin biopsy • Treatment • Early treatment is key • Doxycycline • Chloramphenicol is alternative • Duration: at least 3 days after fever resolution (usually 7-14 days) • Mortality • Untreated: 20-80% in preantibiotic era • 0.7% in 2007

  20. Case 1: Key Points • RMSF is potentially fatal if not treated in timely manner • Early recognition is key (i.e. before onset of rash) • Look to animal health / exposures as potential clues to diagnosis

  21. case 2 • 19 year old male presenting in July 2015 • Fever to 101, sweats, myalgias, headache x 4 days • Blotchy rash • Recent travel to Western Upper Peninsula and hiking west of Kalamazoo, with removal of ticks • No recalled tick bites • Lyme ELISA positive, Western Blot IgM positive, IgG negative

  22. case 2 • Treatment for this patient? • (A) No treatment • (B) Doxycycline • (C) Ceftriaxone • (D) Oseltamivir

  23. case 2 • Treatment for this patient? • (A) No treatment • (B) Doxycycline • (C) Ceftriaxone • (D) Oseltamivir

  24. Lyme disease • Most common tick-borne infection in United States • Estimated 300,000 annual cases • Increasing in incidence • Majority of US cases caused by spirochete Borreliaburgdorferi(other borrelia species in various parts of the world) • Transmitted by blacklegged ticks (nymph stage) • Ixodesscapularis (northeast, mid-atlantic, north-central US) • Ixodespacificus (west coast)

  25. Lyme disease – expanding geography

  26. Lyme disease – expanding geography

  27. Lyme disease – expanding geography

  28. Lyme disease – expanding geography

  29. Lyme disease – expanding geography

  30. Lyme disease – expanding geography

  31. Lyme disease – expanding geography

  32. Lyme disease – expanding geography

  33. Lyme disease – expanding geography

  34. Lyme disease – expanding geography

  35. Lyme disease – expanding geography

  36. Lyme disease – expanding geography

  37. Lyme disease – expanding geography

  38. Lyme disease – expanding geography

  39. Lyme disease – expanding geography

  40. Lyme disease in Michigan • Washtenaw County 2016 • 4 cases acquired within county • 13 cases acquired elsewhere

  41. Lyme Disease cases by month – United States 2001-2015

  42. Tick Life-Cycle

  43. Lyme disease: transmission • Usually from nymph stage of ticks (~2 mm in size) • Attachment for 36-48 hours at least required for transmission to occur • Usually spring to summer months

  44. Early lyme disease • Early Localized Disease (range 3-30 days after bite, usually 7-14 days) • Erythema migrans rash • Seen in up to 80% of patients • Not generally painful • Expand over days to weeks • Constitutional symptoms (headache, fatigue, myalgias, fevers) • Early Disseminated Disease (weeks to months later) • Neurologic: lymphocytic meningitis, cranial nerve palsy, radiculopathy, neuropathy, mononeuritis multiplex • Carditis: heart block, myopericarditis

  45. Late disseminated lyme disease • Typically occurs months to years later • Arthritis • Large joints, often knee • Intermittent or persistent • Neurologic manifestations • Peripheral neuropathy • Encephalopathy or encephalomyelitis

  46. Lyme Disease Treatment • Early Disease • Doxycycline 100 mg bid x 10-21 days • Amoxicillin 500 mg tid x 14-21 days • Cefuroxime 500 mg bid x 14-21 days

  47. case 3 • 35 year old male • Recent hiking in Wisconsin in Lyme-endemic region • Now with rash, mild fever and achiness

  48. case 3 • How should this patient be managed? • (A) Check Lyme ELISA and Western Blot, treat if positive • (B) Skin biopsy with PCR for Lyme disease • (C) Doxycycline • (D) Cephalexin

  49. case 3 • How should this patient be managed? • (A) Check Lyme ELISA and Western Blot, treat if positive • (B) Skin biopsy with PCR for Lyme disease • (C) Doxycycline • (D) Cephalexin

  50. Lyme Testing • ELISA followed by Western Blot • IgM: seen within 1-2 weeks of EM rash • IgG: seen within 2-6 weeks of EM rash

More Related